Enzyme immunoassays for measuring complement-dependent prevention of immune precipitation (PIP) and solubilization of preformed antigen-antibody complexes (SOL).

We have developed simple and sensitive enzyme-based methods for evaluating the ability of serum complement to prevent immune complex precipitation (PIP) or to solubilize preformed immune complexes (SOL). Alkaline phosphatase, serving both as antigen and label, is added to goat IgG anti-alkaline phosphatase antibodies, with serum present throughout the assay (PIP), or added after immune complex formation (SOL). After incubation at 37 degrees C for 1 h followed by centrifugation, the enzyme activity of the supernatant, reflecting the amount of immune complexes in solution, is measured by colorimetry. Results are expressed with reference to a standard serum pool assigned 100 arbitrary units (AU). Intra- and inter-assay variabilities are within 10%. The normal ranges were 67-133 AU for PIP and 72-129 AU for SOL. These methods have been standardized for clinical use in relation to impaired complement function and immune complex disease, and adapted for measuring complement mediated binding of immune complexes to erythrocytes. They are sensitive, easy to perform and do not require expensive facilities. By measuring the interaction of complement with immune complexes, these methods may highlight aspects of the classical and the alternative pathway that are different from those detected using haemolysis as an endpoint.

[1]  J. Schifferli,et al.  Complement-mediated inhibition of immune precipitation. I. Role of the classical and alternative pathways. , 1982, Clinical and experimental immunology.

[2]  J. Schifferli,et al.  Inhibition of immune precipitation by complement. , 1980, Clinical and experimental immunology.

[3]  M. Takahashi,et al.  Solubilization of antigen-antibody complexes: a new function of complement as a regulator of immune reactions. , 1980, Progress in allergy.

[4]  J. Schifferli,et al.  Complement mediated inhibition of immune precipitation and solubilization generate different concentrations of complement anaphylatoxins (C4a, C3a, C5a). , 1986, Clinical and experimental immunology.

[5]  K. Whaley,et al.  The effects of immunoglobulin isotype and antibody affinity on complement-mediated inhibition of immune precipitation and solubilization. , 1987, Molecular immunology.

[6]  V. Nussenzweig,et al.  Requirements for the solubilization of immune aggregates by complement. The role of the classical pathway. , 1978, The Journal of clinical investigation.

[7]  K. Steinsson,et al.  SUCCESSFUL PLASMA INFUSION TREATMENT OF A PATIENT WITH C2 DEFICIENCY AND SYSTEMIC LUPUS ERYTHEMATOSUS: CLINICAL EXPERIENCE OVER FORTY‐FIVE MONTHS , 1989, Arthritis and rheumatism.

[8]  K. Whaley,et al.  IgM-RF prevents complement-mediated inhibition of immune precipitation. , 1984, Immunology.

[9]  K. Erlendsson,et al.  An enzyme based assay for the measurement of complement mediated binding of immune complexes to red blood cells. , 1998, Journal of immunological methods.

[10]  J. Schifferli,et al.  Complement-mediated inhibition of immune precipitation. II. Analysis by sucrose density gradient ultracentrifugation. , 1982, Clinical and experimental immunology.

[11]  H E Solberg,et al.  International Federation of Clinical Chemistry (IFCC), Scientific Committee, Clinical Section, Expert Panel on Theory of Reference Values, and International Committee for Standardization in Haematology (ICSH), Standing Committee on Reference Values. Approved Recommendation (1986) on the theory of re , 1987, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.

[12]  O. Nived,et al.  Kinetic analysis of immune complex solubilization: complement function in relation to disease activity in SLE. , 1992, Clinical and experimental rheumatology.

[13]  I. Brandslund,et al.  A standardized method for quantitating the complement-mediated immune complex solubilizing capacity of human serum. , 1983, Journal of immunological methods.

[14]  K. Whaley,et al.  Mechanism of action of an inhibitor of complement-mediated prevention of immune precipitation. , 1990, Immunology.

[15]  A. Sjöholm,et al.  Difference in the biological properties of the two forms of the fourth component of human complement (C4). , 1986, Clinical and experimental immunology.

[16]  M. Walport,et al.  Deficiency of the effector mechanisms of the immune response and autoimmunity. , 1987, Ciba Foundation symposium.

[17]  L. Curtiss,et al.  Selection and characterization of monoclonal antibodies for measuring plasma levels of apolipoproteins A-I and B , 1990 .

[18]  V. Nussenzweig,et al.  Studies on the mechanism of solubilization of immune precipitates by serum , 1976, The Journal of experimental medicine.

[19]  G. Miller,et al.  A new complement function: solubilization of antigen-antibody aggregates. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[20]  H. E. Solberg Approved recommendation (1987) on the theory of reference values. Part 5. Statistical treatment of collected reference values. Determination of reference limits , 1987 .

[21]  P. Späth,et al.  Solubilization of immune precipitates by complement in the absence of properdin or factor D , 1988, FEBS letters.

[22]  P. Lachmann Complement deficiency and the pathogenesis of autoimmune immune complex disease. , 1990, Chemical immunology.

[23]  G. Füst,et al.  Decreased inhibition of immune precipitation by sera with the C2 B allotype. , 1991, Clinical immunology and immunopathology.